Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Dapagliflozin
Treatment for Chronic kidney disease due to diabetes mellitus type 2
Typical Dosage: Dapagliflozin 10mg daily
Effectiveness
92%
Safety Score
65%
Clinical Trials
1
Participants
150K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Dapagliflozin 10mg daily
Time to Effect
3-6 months for sustained renal benefits
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
20(Treat 20 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,200
Monitoring:$1,200
Side Effect Mgmt:$150
Total Annual:$8,550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$10,687.5
Comparison vs ACE inhibitor/ARB alone
Cost Difference
+$7,200/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Dapagliflozin Outcomes
for Chronic kidney disease due to diabetes mellitus type 2
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+80%
Common Side Effects
Genital mycotic infections
+8%
Urinary tract infections
+5%
Volume depletion/hypotension
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Dapagliflozin in Chronic kidney disease due to diabetes mellitus type 2
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
NCT06374043COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Almelo, Netherlands +1 more
Started: May 11, 2021